NEW YORK--(BUSINESS WIRE)--iPredictTM AI Eye Screening System provides fully automated age-related macular degeneration (AMD) screening, including retinal imaging and immediate reporting of actionable results. Using the iPredictTM System, primary care and various specialty practices can accurately and efficiently screen people over 50 for AMD and refer them to a specialist (i.e., an ophthalmologist).
Once high-resolution images of the patient’s eyes have been captured using a color fundus camera and submitted to the iPredictTM AI System, the screening results are available in a fully automated report in less than 60 seconds. The entire test can easily and reliably be completed within 5 minutes.
iHealthScreen conducted a prospective trial in the general population to prospectively assess the product’s accuracy, sensitivity and specificity. The completed pivotal trial of the device demonstrated that iPredict-AMD achieved excellent accuracy with a sensitivity of 86.86% and a specificity of 94.13%.
These prospective study results were initially presented at the Annual Meeting of the American Academy of Ophthalmology (AAO) and selected for Panel Discussion as outstanding work.
In its 510(k) application to the FDA iHealthScreen has proposed the following indication for iPredict’s use:
iPredict-AMD is indicated for use by health care providers to automatically detect more than early age-related macular degeneration (mteAMD) in adults above 50 years of age who have not been previously diagnosed with Late AMD (i.e., not legally blind or not showing blind spots in their visual field).
iPredict-AMD is indicated for use with the DRSPlus color fundus camera (iCare Inc. K192113) in both primary care and eye care settings.
If referable stage disease is detected for any of these conditions, the iPredict automated report recommends a visit to an Ophthalmologist for appropriate treatment. Otherwise, in accordance with standards of care, a follow-up visit in one year is suggested.
iPredict is indicated for use by healthcare providers in clinics, hospitals, or other healthcare facilities to detect AMD automatically.
“This technology could be particularly useful in identifying someone who has slipped across the boundary for progression into severe AMD,” Dr. Theodore Smith (Professor in Ophthalmology and Neuroscience at Icahn School of Medicine at Mount Sinai, New York) said.
“This is a major milestone for iHealthScreen. iPredictTM eye disease diagnostic tools can help prevent blindness for millions of people and save insurers countless millions of dollars in avoidable healthcare cost,” said Dr. Alauddin Bhuiyan, the founder and CEO of the company.
About iHealthScreen
iHealthScreen (iHS) Inc. has a market-ready product iPredictTM, an AI and telemedicine-based HIPAA compliant software (class II medical device) for automated screening, prediction, and referral of individuals at risk of developing late age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma, Cardiovascular Heart Disease and stroke. iHS received CE certification, and Australian and Abu Dhabi Health approvals (Class II med device) for AMD, DR and glaucoma screening. AMD and DR tools are expected to be FDA cleared in 3rd Qtr of 2023. The company has customers: Burjeel hospital, UAE (one of the largest hospital chains in the middle east) and Bangladesh Diabetes Society (has 5.5m registered diabetic patients).
iHealthScreen company is open to distribution and co-development partnerships relating to its products. For more information contact Dr. Bhuiyan.
The company is also actively working on fundraising for a pre-series A round of $5M. iHealthScreen’s campaign for Reg CF crowdfunding also opened at StartEngine: https://www.startengine.com/offering/ihealthscreen
